Drug intelligence / Profile preview

VLA2101

Development stage: Unknown
Lead developer: Valneva
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VLA2101 is an investigational **variant strain-based COVID-19 vaccine** developed by **Valneva** as a follow-on to VLA2001. It is described as an **inactivated whole-virus vaccine** that uses the same general manufacturing technology platform as Valneva's Japanese encephalitis vaccine IXIARO. The program was evaluated in a **Phase 3** clinical study using a **2-dose schedule given 28 days apart** in participants aged **12 years and older**, with immunogenicity compared against VLA2001. Its intended effect is to induce protective immune responses against **SARS-CoV-2**, including variant strains, for prevention of COVID-19.

Other names: VLA2101 COVID-19 vaccine candidateVLA-2101 COVID-19 vaccine candidateVLA 2101 COVID-19 vaccine candidate

Beyond the preview

Go deeper on VLA2101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VLA2101.

Explore the full profile